期刊文献+

乳腺癌新辅助化疗疗效及其判断方法 被引量:6

下载PDF
导出
摘要 越来越多乳腺癌患者选择进行术前新辅助化疗,与传统辅助化疗相比,新辅助化疗有其独特的优势。作者综述了新辅助化疗疗效,包括疗效评价系统、化疗前后的变化和化疗反应的评估。
出处 《现代医学》 2011年第2期237-240,共4页 Modern Medical Journal
  • 相关文献

参考文献21

  • 1HORTOBAGYI G N.Comprehensive management of locally advanced breast cancer[J].Cancer,1990,66(6):1387-1391.
  • 2FISHER E R,WANG J,BRYANT J,et al.Pathobiology of preoperative chemotherapy:findings from the National Surgical Adjuvant Breast and Bowel(NSABP) protocol B-18[J].Cancer,2002,95(4):681-695.
  • 3van der HAGER J A,van da VELDE C J,JULIEN J P,et al.Preoperative chemotherapy in primary operable breast cancer:results from the European Organization for Research and Treatment of Cancer trial 10902[J].J Clin Oncol,2001,19(22):4224-4237.
  • 4DAVIDSON N E,MORROW M.Sometimes a great notion-an assessment of neoadjuvant systemic therapy for breast cancer[J].J Natl Cancer Inst,2005,97:159-161.
  • 5WALJEE J F,NEWMAN L A.Neoadjuvant systemic therapy and the surgical management of breast cancer[J].Surg Clin N Am,2007,87:399-415.
  • 6BUZDAR A U,VALERO V,THERIAULT R,et al.Pathological complete response to chemotherapy is related to hormone receptor status.
  • 7SHARKEY F E,ADDINGTON S L,FOWLER L J,et al.Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma[J].Mod Pathol,1996,9(9):893-900.
  • 8ROSEN P P.Pathologic effects of therapy[J].Rosen s Breast Pathology,2001,887-897.
  • 9ARENS N,BLEVL U,HILDENBRAND R.HER2/neu,p53,Ki67,and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer[J].Virchows Arch,2005,446:489-496.
  • 10DOWSETT M,EBBS S R,DIXON J M,et al.Biomarker changes during neoadjuvant anastrozole,tamoxifen,or the combination:influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists[J].J Clin Oncol,2005,23:2477-2492.

同被引文献83

  • 1曾谷清,康颖,高天舒,王汉群,高勇强.乳腺癌组织中P16蛋白的表达与细胞增殖的关系[J].中国现代医学杂志,2007,17(6):650-653. 被引量:5
  • 2FISHER B, BRYANT J, WOLMARK N, et al. Effect of preop- erative chemotherapy on the outcome of women with operablebreast cancer[ J]. J Clin Oncol, 1998,16(8) :2672-2685.
  • 3MAURIAC L, MacGROGAN G, AVRIL A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm:a uniceutre randomized trial with a 124-month median follow-up [ J]. Ann Oncol, 1999,10 ( 1 ) :47-52.
  • 4BROiT P,SCHOLL S M, de la ROCHEFORDIERE A, et al. Short and long-term effects on survival in breast cancer pa- tients treated by primary chemotherapy:an updated analysis of a randomized trial [ J ]. Breast Cancer Res Treat, 1999,58 (2) : 151-156.
  • 5BONADONNA G,VALAGUSSA P, BRAMBILLA C, et al. Pri- mary chemotherapy in operable breast cancer:eight-year expe- rience at the Milan Cancer Institute[ J ]. J Clin Oncol, 1998,16 (1) :93-100.
  • 6van der HAGE J A, van de VELDE C J H, JULIEN J P, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treat- ment of Cancer trial 10902 [ J ]. J Clin Oneol, 2001,19 ( 22 ) : 4224-4237.
  • 7BONADONNA G, VERONESI U, BRAMBILLA C, et al. Pri- mary chemotherapy to avoid mastectomy in tumors with diame- ters of three centimeters or more[ J]. J Nat Cancer Inst, 1990, 82 (19) : 1539-1545.
  • 8GIANNI L, BASELGA J, EIERMANN W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer [ J ]. J Clin Oneol, 2009,27 ( 15 ) : 2474-2481.
  • 9BHALLA K, HARRIS W B. Molecular and biologic determi- nants of neoadjuvant chemotherapy of locoregional breast canc- er[ C ]//Seminars in oncology. Elsevier, 1998,25 (2) : 19-24.
  • 10RASTOGI P, ANDERSON S J, BEAR H D, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 [ J]. J Clin On- col,2008,26(5) :778-785.

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部